Efficiency of ADOPTIVE immunotherapy for melanoma: a case REPORT

A lot of research is focused on finding better treatment options for cancer. Along with radical treatment, cancer immunotherapy has proved to be useful for a growing number of cancer patients. We report a case of stage IIIB melanoma in a 53-year woman who received adoptive immunotherapy with cytokine-induced killer (CIK) cells. For activation, mononuclear cells were collected from the patient’s peripheral blood and cultivated in X-vivo20 medium containing IL-2 (250 U/ml) and IL-15 (50 ng/ml) for 10-14 days. From January 2015 to May 2016, a total of 39 CIK cell infusions were administered intradermally to 2-4 points in the paravertebral area, every 1–2 weeks. Flow cytometric analysis of peripheral blood lymphocytes in 3 months after starting CIK cell immunotherapy showed a decrease in the number of NK-cells from 18 % to 12 % and CD314 + NK-cells from 16% to 6%. The levels of CD38+, CD38+Т, HLA-DR+ and HLA-DR+Т lymphocytes increased from 53 %, 24 %, 21 %, 9 % and 19 % to 66 %, 51 %, 28 %, 20 % and 29 %, respectively. There was evidence of reactive changes in lymph nodes and stable disease. Metastases on the left shoulder tended to decrease, and they completely disappeared 9 months after tarting adoptive immunotherapy. Partial regression of metastasis on the right shoulder was observed 11 month after staring adoptive immunotherapy. Adoptive immunotherapy demonstrated the increased disease-free survival for the patient with melanoma. In conclusion, CIK immunotherapy  may be an effective treatment method for metastatic melanoma.

1. Li Y., Huang Q., Zhong Y., Wang A., Sun J., Zhou J. Prospects in adoptive cell transfer therapy for сancer. J Immunol Clin Res. 2013; 1: 1008.

2. Berezhnoi А.Е., Gnuchev N.V., Georgiev G.P. Molecular mechanisms of interaction between tumor cells and the immune system. Problems in oncology. 2008; 54 (6): 669– 683. [in Russian]

3. Berezhnoi А.Е., Chernysheva А.D., Zakeeva I.R. The interferongamma induction of HLA-E molecule expression on the surface of tumor cells leads to protection of tumor cells from cytotoxic effect of lymphocytes. Problems in Oncology. 2009; 55 (2): 224–229. [in Russian]

4. Cheng M., Chen Y., Xiao W., Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013 May; 10 (3): 230–52. doi: 10.1038/cmi.2013.10.

5. Abakushina Е.V., Marizina Yu.V., Neprina G.S. Characteristics of lymphocyte sub- populations in peripheral blood of cancer patients undergoing combined modality treatment including adoptive immunotherapy. Siberian Journal of Oncology. 2015; 1: 45–50. [in Russian]

6. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008 Nov 10; 26 (32): 5233–9. doi: 10.1200/JCO.2008.16.5449.

7. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009 Apr; 21 (2): 233–40. doi: 10.1016/j.coi.2009.03.002.

8. Liu J., Sui J., Zhang Z., Ren X., Luan L., Yang Q., Gu S., Wank R., Laumbacher B., Song X. Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokine-induced killer cells: a case report and review of the literature. Oncol Lett. 2010 Nov; 1 (6): 955–958.

9. Li W., Xu L.P., DI Zhao L., Wang L., Zhang Y., Gao Q.L., Mai L. Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: a case report and review of the literature. Oncol Lett. 2013 Apr; 5 (4): 1427–1429.

10. Ma Y., Zhang Z., Tang L., Xu Y.C., Xie Z.M., Gu X.F., Wang H.X. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy. 2012 Apr; 14 (4): 483–93. doi: 10.3109/14653249.2011.649185.

11. Abakushina Е.V., Marizina Yu.V., Neprina G.S. Efficacy of combined use of IL-2 и IL-15 for activation of cytotoxic lymphocytes in vitro. Genes and Cells. 2015. 10 (2): 78–85. [in Russian]